Patent · US Active

Use of the IL-6 gene expression level for classification of a subject in risk groups in the prognosis or diagnosis of type II diabetes mellitus

US12049669B2 · kind B2 · utility

0Cited by

0References

8Claims

0Family size

Assignee

LIPOCYTE BIOMED GMBH · DE

Inventors

Uwe Jensen · Osnabrück, DE
Wolfgang Hierneis · Hamburg, DE
Markus KLEMKE · Bremen, DE
Helge Wilhelm THIES · Bremen, DE

Key dates

Filing date	Nov 19, 2018
Grant date	Jul 30, 2024
Priority date	—
Expiry date	May 23, 2040

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12Q2600/158
WIPO fieldBiotechnology
WIPO sectorChemistry

Abstract

The invention relates to the use of the relative value of the gene expression level of the IL-6 gene in the prognosis or the diagnosis of a type II diabetes mellitus disease in a subject. It further relates to a method for prognosing and/or diagnosing a type II diabetes mellitus disease for classification of a subject into risk groups, wherein the gene expression level of the IL-6 gene is determined and the subject is subsequently classified into risk groups, taking said gene expression level into account.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.